Hoppa till innehållet
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.
Biosergen AB (publ) ("Biosergen" or the "Company") has prepared an EU growth prospectus (the "Prospectus") for the forthcoming issue of units consisting of shares and warrants with preferential rights for existing shareholders (the "Rights Issue"), which the board of directors decided on and announced on January 30, 2024, subject to approval from an extraordinary general meeting which was obtained on March 1, 2024. The Prospectus was approved and registered by the Swedish Financial Supervisory Authority today. The Prospectus, containing complete terms and conditions, is now available on the Company's website, www.biosergen.net, and will be made available on Mangold Fondkommission AB's website, www.mangold.se. Application forms and other information about the Rights Issue will also be made available on the Company's website, www.biosergen.net.
The record date for obtaining unit rights in the Rights Issue is March 5, 2024. The subscription period will run from March 7, 2024, up to and including March 21, 2024.
Advisors
Mangold Fondkommission AB is the financial advisor to Biosergen in connection with the Rights Issue. Hammarskiöld is the legal advisor to the Company in connection with the Rights Issue.